Candidate: Dr. Jaye is a trained pathologist who will pursue an academic career in basic research, and plans to maintain his research focus on selected aspects of neutrophil biology. He will seek a position in which he can practice as a physician scientist with 75% effort in research and 25% in diagnostic molecular hematopathology and flow cytometry. The current application nicely integrates with his clinical expertise and will greatly facilitate his transition into an independent investigator. He will devote greater than 75 percent time to the proposed work. Research: The goals are to elucidate the molecular basis by which a novel neutrophil chemoattractant elicits important cell responses, processes which have direct relevance to GI mucosal pathobiology. A partially characterized phage, bearing peptide FGPNLTGRW (FGP), binds selectively to neutrophils (PMN) and monocytes, elicits calcium transients, and chemotaxis and degranulation in PMN. Preliminary data suggest that FGP initiates a novel G protein coupled signaling pathway and, among chemoattractant receptors on PMN, the receptor for FGP displays a novel requirement for ligand multivalency for activation. Studies are proposed to: 1) elucidate the most proximal signaling events in FGP activation of PMN to begin to systematically dissect this novel signaling; 2) to test the role of ligand valency in elicitation of cell responses by producing monomeric and multimeric FGP-bearing constructs for testing in PMN cell binding and response assays; and 3) to identify the receptor for FGP by biochemical/molecular methods given the novel nature of PMN activation by FGP and elimination of likely candidate receptors in preliminary studies. These studies have health relevance to inflammatory bowel diseases, mucosal infections, and other inflammatory disorders of mucosal surfaces. Environment: Dr. Jaye has been assigned laboratory space at Emory University Medical School in the Department of Pathology in the Epithelial Pathobiology Research Unit, adjacent to his sponsor?s, Dr. Parkos, and cosponsor?s, Dr. Madara, who will be primarily responsible for his scientific training. The facilities and resources available to him for his proposed work are outstanding. Furthermore, his sponsors, a panel of senior faculty consultants on campus and at other institutions will together foster his development and transition to a creative, independent researcher. He will also have access to a wealth of seminars in the scientific community at Emory University and formal didactic training within the Graduate School.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK060647-04
Application #
6833473
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Podskalny, Judith M,
Project Start
2002-02-15
Project End
2006-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
4
Fiscal Year
2005
Total Cost
$126,792
Indirect Cost
Name
Emory University
Department
Pathology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Lai, Anne Y; Mav, Deepak; Shah, Ruchir et al. (2013) DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. Genome Res 23:2030-41
Lai, Anne Y; Fatemi, Mehrnaz; Dhasarathy, Archana et al. (2010) DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exp Med 207:1939-50
Karathanasis, Efstathios; Geigerman, Cissy M; Parkos, Charles A et al. (2009) Selective targeting of nanocarriers to neutrophils and monocytes. Ann Biomed Eng 37:1984-92
Agarwal, Abhiruchi; Jaye, David L; Giegerman, Cissy M et al. (2008) Rational identification of a novel peptide for targeting nanocarriers to 9L glioma. J Biomed Mater Res A 87:728-38
Jaye, D L; Iqbal, J; Fujita, N et al. (2007) The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation. J Pathol 213:106-15
Jaye, David L; Geigerman, Cissy M; Herling, Marco et al. (2006) Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol 19:1555-62
Liu, Pengbo; Ramachandran, Sumathi; Ali Seyed, Mohamed et al. (2006) Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66:4011-9
Frick, Christoph; Odermatt, Alex; Zen, Ke et al. (2005) Interaction of ICAM-1 with beta 2-integrin CD11c/CD18: characterization of a peptide ligand that mimics a putative binding site on domain D4 of ICAM-1. Eur J Immunol 35:3610-21
Lonial, Sagar; Waller, Edmund K; Richardson, Paul G et al. (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106:3777-84
Fujita, Naoyuki; Jaye, David L; Geigerman, Cissy et al. (2004) MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119:75-86

Showing the most recent 10 out of 14 publications